We would love to hear your thoughts about our site and services, please take our survey here.
Interestingly, ciz has a bunch of exosome related patents for the treatment of cancers that they didn't follow though with...
On your first post yes, correcting gene expressions imo is the way to beat cancer and prevent rumours from growing along with maintaining your original "genetic print"... I don't know what this would do to other cellular processes though. Would they not age or would there be a complete breakdown in communication? It's complex.
It was this:
https://x.com/TomWinnifrith/status/1633079106689441793?s=20
Yes, retail wouldn't understand the significance of it.
But those that look at any contracts made to sell the product afterwards will look at it.
It's not just a one in four. You have two measures, it's important to be told that you also don't have it too. Sensitivity and specificity.
Could also be discussing licensing in other states where Corepath aren't approved.
Potentially a lot going on.
I dont think they are just sat there twiddling thumbs.
A note on higher volume testing, I know we said it in telegram group, it may be that the accuracy is slightly compromised. If we are 75-85% accurate as opposed to 95% in early stages, that is still phenomenal. Not saying that's what it is, I don't know but it's something I'd perhaps expect due to the environment change of the test.
I think if they didn't put put the odd tweet, people would ask where are they?
The odd tweet does no harm. I don't see it being like the begging bowl lifestyle cos that then pump out misleading RNS to then place off strength.
We know that isn't the case with pay and options here. I'm pretty sure that like the rest of us, they want to see the product out there in its best possible format and then see the share price move to make the most of those options.